GENinCode (LON:GENI) Sets New 52-Week Low – What’s Next?

GENinCode Plc (LON:GENI) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as GBX 0.76 and last traded at GBX 0.80, with a volume of 5847561 shares. The stock had previously closed at GBX 0.85.

GENinCode Stock Performance

The company has a 50 day moving average price of GBX 0.99 and a 200 day moving average price of GBX 1.22. The company has a market capitalization of £6.40 million, a price-to-earnings ratio of -0.41 and a beta of 0.59. The company has a debt-to-equity ratio of 117.74, a quick ratio of 15.88 and a current ratio of 0.93.

GENinCode (LON:GENI) last released its quarterly earnings data on Monday, June 8th. The company reported GBX (2.08) earnings per share for the quarter. GENinCode had a negative net margin of 185.47% and a negative return on equity of 409.40%. The business had revenue of GBX 308 million during the quarter. Equities research analysts predict that GENinCode Plc will post -7.1299999 earnings per share for the current fiscal year.

About GENinCode

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.